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Abstract
Introduction: We report the development of acute lymphoblastic leukemia in a patient in whom temozolomide
was used for the treatment of a brain tumor. Unlike that of other alkylating agents, the leukemogenic potential of
temozolomide is considered to be very low, and very rarely are such cases reported.
Case Presentation: A 26-year-old Pakistani man who was treated for glioblastoma with temozolomide in an
adjuvant setting was diagnosed to have acute lymphoblastic leukemia one year after stopping temozolomide.
Conclusion: Temozolomide is a highly active agent, used in the management of high-grade brain neoplasms. The
agent is generally regarded to be safe, with an acceptable safety profile. Very few cases of myelodysplasia
associated with temozolomide use have been reported. We report here the first case of acute lymphoblastic
leukemia, which developed in a young man about one year after he finished taking temozolomide. This should
provide further insight into a possible toxicity profile of this alkylating agent. This finding should be of interest to
physicians in general and to medical oncologists in particular.

Introduction
Survival rates from aggressive, relapsed, refractory, or
high-grade brain tumors are generally poor, with the
median survival for some being less than one year [1].
With increased survival, however, the long-term toxicities of the available chemotherapeutic agents used in
aggressive brain cancers have become more prominent
[2]. Alkylating agents remain the most active agents
known for the treatment of aggressive and high-grade
brain neoplasms. Treatment-related myelodysplasia
(t-MDS) and acute leukemia (t-AL) have remained a
concern of prolonged exposure to alkylating agents [3].
Temozolomide (TMZ) is an oral second-generation
alkylating agent with activity against recurrent highgrade gliomas and has been considered efficacious and
relatively safe [4]. Here we report a case of t-ALL in a
patient who received TMZ for the treatment of highgrade mixed glioma.
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Case Report
A 26-year-old Pakistani man presented with history of
new-onset seizures. Magnetic resonance imaging (MRI)
of the brain revealed a contrast-enhancing lesion in the
right frontoparietal region with compressions and a shift
of the midline. The mass was resected in August 2007
and confirmed to be a mixed glioma with components
of both astrocytoma and oligodendroglioma, WHO
grade II. About six weeks after surgery, the patient was
brought back with a new history of seizures. An MRI
examination revealed a gross local recurrence at the site
of the previous surgery, which was infiltrating within the
sulci of the brain matter. Based on the clinical behavior
and surgical unresectability of the tumor, he was treated
with concurrent chemoradiation therapy (radiation:
6000 cGY/temozolomide, 75 mg/m 2 ). He showed an
excellent response to concurrent chemoradiotherapy,
with a complete disappearance of the recurred lesion.
He was given a total of six cycles of TMZ (150 mg/m2,
days one to five, every 28 days). He completed chemotherapy in January 2008 and remained well, without
evidence of recurrence, on surveillance MRI scans. He
recently came in complaining of easy bruisability; blood
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counts revealed an elevated white blood cell count (total
leukocyte count; 20,000 per deciliter; 16% neutrophils;
78% lymphocytes) and thrombocytopenia (platelet
count, 16,000 per deciliter). Bone-marrow aspirate
revealed diffuse infiltration with blast cells consistent
with acute leukemia. Peripheral blood flow cytometry on
immunophenotyping with five-color cytomics (fc500
Beckman Coulter flow cytometer) showed this population of cells with bright reactivity with Pan-T-markers
(that is, CD5, CD7, and cytoplasm cCD3, along with
CD45). Positivity of this population with Tdt was also
very prominent, so immunophenotypic results were consistent with precursor-T-acute lymphoblastic leukemia
(Pre-T-ALL). Bone marrow cytogenetics revealed a normal karyotype and negative Philadelphia chromosome.
He is currently undergoing treatment.

Discussion
We report, to the best of our best knowledge and search
of the literature, what appears to be the first reported
case of Philadelphia-negative true ALL developing subsequent to the use of TMZ. Some case reports exist of
myelodyplasia rapidly transforming in undifferentiated
leukemia [3,5] and one report of Ph negative T-ALL in
a patient receiving treatment [6].
TMZ is an oral alkylating agent that is now known to
be active against a variety of CNS neoplasms. After oral
absorption, it spontaneously hydrolyzes to methyltriazen-1-yl imidazole-4-carboxamide (MTIC). MTIC
degrades to a highly reactive cation that methylates guanines in DNA at the O6 position, causing base-pair mismatch. Unsuccessful cycles of mismatch repair
eventually lead to breaks and permanent nicks in the
daughter strand, preventing mitotic division, and the
cell undergoes apoptosis [7,8]. The action of TMZ has
been shown to be augmented in the concurrent presence of radiation, so the proof of efficacy and superiority of TMZ has led to a paradigm shift in the
management of aggressive CNS gliomas [1]. Although
the recommended treatment-cycle length is six months
after initial treatment, with concurrent chemoradiotherapy, some neuro-oncologists prefer to use it indefinitely
[9]. A recent survey of physicians who used TMZ for
more than one year, on average, found it to be completely safe, except for grade II and III myelosuppression
[10]. All alkylating agents are considered to carry a five
to ten percent mutagenic risk potential for development
of myeloid leukemia, but not for lymphoblastic leukemia. TMZ is a new alkylating agent; its safety profile
and lack of data on any mutagenic potential has led to
its incorporation in a large number of studies, for the
range from malignant gliomas to malignant melanomas
[11]. Little consistent data exist regarding the toxicity of
TMZ, so questions have been raised about its mutagenic
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potential. Some clinical trials have started to include
carcinogenic potential as a point of assessment in longterm safety monitoring of the drug [11]. Hartmut Geiger
et al. [12] published data that reveal the mutagenic
potential of TMZ for bone marrow cells in vivo in the
mouse model system.

Conclusion
TMZ has unequivocally shown its therapeutic potential
in randomized clinical trials as an effective, relatively
safe, and generally well-tolerated therapy for aggressive
CNS neoplasms, resulting in better overall survival.
Because it is a relatively new and unique alkylating agent,
the short-term and long-term data regarding safety, especially leukemogenic potential, must have further time to
mature. Although the association is unlikely to be a random finding, the association between TMZ and treatment-related leukemia deserves further study.
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